Platelet factor 4 antibody persistence and long-term pathogenicity in vaccine-induced immune thrombotic thrombocytopenia
Journal of Thrombosis and Haemostasis · 2026-07 · 24 (7) · 2514-2521
DOI: 10.1016/j.jtha.2026.03.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-07. Verfasst von Adam Kanack und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Platelet Factor 4, Purpura, Thrombocytopenic, Idiopathic, Autoantibodies, COVID-19 Vaccines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, National Institutes of Health, National Heart Lung and Blood Institute.
Abstract (Originalsprache)
BACKGROUND: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a transient prothrombotic process, although recent data suggest that VITT anti-platelet factor 4 (PF4) antibodies are more persistent than those in heparin-induced thrombocytopenia. OBJECTIVES: We sought to interrogate whether anti-PF4 antibody persistence in VITT is related to the continued persistence of antibody clones from the acute phase or to the development of novel anti-PF4 antibodies due to epitope spreading. METHODS: Samples from 6 patients with Ad26.COV2.S-associated VITT with a median time to follow-up of 244 days from acute presentation (range, 114-664 days) were studied in antigenic/functional assays and by mass spectrometry. One patient with ChAdOx1 nCoV-19-associated VITT was tested >4 years after acute presentation. RESULTS: Upon affinity-enrichment of anti-PF4 antibodies, mono/oligoclonal anti-PF4 antibodies were observed despite negative results in serum protein electrophoresis/"Mass-Fix" testing of native sera. Anti-PF4 antibody abundance decreased over time, with no evidence of novel anti-PF4 antibody production after acute presentation. Although previous studies indicate a stereotypical pairing of VITT antibodies with lambda light chains, 1 patient with VITT produced antibodies with a kappa light chain. Long-term thrombocytopenia/thrombosis was not seen in any of the 6 Ad26.COV2.S-associated VITT patients; however, platelet-activating anti-PF4 antibodies were seen 4 years after the acute event in an additional patient with ChAdOx1 nCoV-19-associated VITT with chronic low-grade thrombocytopenia. CONCLUSION: VITT, unlike monoclonal gammopathy of thrombotic significance, appears to be a monoclonal gammopathy of unknown significance-negative state, but it needs confirmation in larger studies. VITT antibodies can be composed of lambda or kappa light chains, and some patients with VITT exhibit persistent thrombocytopenia many years after the acute event.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Internal Medicine, Centre d'Excellence des Maladies Vasculaires, Centre Hospitalier Universitaire de Québec, Hôpital Saint-François d'Assise, Université Laval, Québec, Canada.
- Department of Internal Medicine, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center College of Medicine, Omaha, Nebraska.
- Department of Pathology, University of Chicago, Chicago, Illinois, USA.
- Department of Medicine, University of Colorado, Aurora, Colorado, USA.
- Department of Medicine, University of Utah, Salt Lake City, Utah, USA.
Förderung
- NHLBI NIH HHS
- National Institutes of Health
- National Heart Lung and Blood Institute
Zitieren
APA
Kanack, A., Mauch, E., Roberge, G., Splinter, N., Gundabolu, K., Wool, G. D., George, G., Abou-Ismail, M. Y., Smock, K. J., Green, D. L., Coker, J., Kohlhagen, M. C., Murray, D. L., & Padmanabhan, A. (2026). Platelet factor 4 antibody persistence and long-term pathogenicity in vaccine-induced immune thrombotic thrombocytopenia. Journal of Thrombosis and Haemostasis, 24(7), 2514-2521. https://doi.org/10.1016/j.jtha.2026.03.025
Vancouver
Kanack A, Mauch E, Roberge G, Splinter N, Gundabolu K, Wool GD, et al. Platelet factor 4 antibody persistence and long-term pathogenicity in vaccine-induced immune thrombotic thrombocytopenia. Journal of Thrombosis and Haemostasis. 2026;24(7):2514-2521. doi:10.1016/j.jtha.2026.03.025
BibTeX
@article{Kanack2026,
author = {Kanack, Adam and Mauch, Emily and Roberge, Guillaume and Splinter, Noah and Gundabolu, Krishna and Wool, Geoffrey D and George, Gemlyn and Abou-Ismail, Mouhamed Yazan and Smock, Kristi J and Green, David L and Coker, Jonathan and Kohlhagen, Mindy C and Murray, David L and Padmanabhan, Anand},
title = {Platelet factor 4 antibody persistence and long-term pathogenicity in vaccine-induced immune thrombotic thrombocytopenia},
journal = {Journal of Thrombosis and Haemostasis},
year = {2026},
volume = {24},
number = {7},
pages = {2514--2521},
doi = {10.1016/j.jtha.2026.03.025}
}
EUVIMED